Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Junshi Biosciences licenses...
Business licensing agreement

Junshi Biosciences licenses roconkibart to Fosun Wanbang

Analysis based on 8 articles · First reported Jul 01, 2026 · Last updated Jul 02, 2026

Sentiment
70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The licensing agreement between Shanghai Junshi Biosciences Co., Ltd and Fosun International — Fosun Wanbang Pharma Group is expected to positively impact the pharmaceutical and biotechnology sectors, particularly in the Greater China region. Shanghai Junshi Biosciences Co., Ltd will benefit from significant upfront and potential milestone payments, while Fosun International — Fosun Wanbang Pharma Group will expand its portfolio in autoimmune disease treatments, potentially leading to increased revenue and market share for both companies.

Pharmaceuticals Biotechnology
Event Summary

Shanghai Junshi Biosciences Co., Ltd has entered into a licensing agreement with Fosun International — Fosun Wanbang Pharma Group, a wholly-owned subsidiary of Fosun Pharmaceutical Group, for the development, registration, manufacturing, and commercialization of roconkibart (JS005, an anti-IL-17A monoclonal antibody) in the Greater China region. Under the agreement, Shanghai Junshi Biosciences Co., Ltd will receive an upfront payment of RMB215 million, with potential milestone payments up to RMB1.125 million and double-digit tiered royalties on net sales. Roconkibart, developed by Shanghai Junshi Biosciences Co., Ltd, has shown excellent efficacy and safety in Phase 3 clinical studies for moderate to severe plaque psoriasis, and its new drug application was accepted by the China — National Medical Products Administration in December 2025. This collaboration aims to accelerate the clinical development and commercialization of roconkibart, addressing unmet medical needs in autoimmune diseases.

Key Actions
95 Shanghai Junshi Biosciences entered into agreement Fosun International — Fosun Wanbang Pharma Group
90 Shanghai Junshi Biosciences received payment
70 China — National Medical Products Administration accepted application
Entities Involved
stock
Shanghai Junshi Biosciences
Shanghai Junshi Biosciences Co., Ltd has entered into a licensing agreement with Fosun International — Fosun Wanbang Pharma Group for roconkibart, receiving an upfront payment and potential milestone payments and royalties. This collaboration expands its autoimmune disease treatment portfolio and validates its innovative capabilities.
Importance 100.0 Sentiment 75.0
subs
Fosun International — Fosun Wanbang Pharma Group
Fosun International — Fosun Wanbang Pharma Group, a wholly-owned subsidiary of Fosun Pharmaceutical Group, has secured the rights to develop, register, manufacture, and commercialize roconkibart in the Greater China region, enriching its immunology and inflammation portfolio.
Importance 90.0 Sentiment 70.0
stock
Fosun Pharmaceutical Group
Fosun Pharmaceutical Group's subsidiary, Fosun International — Fosun Wanbang Pharma Group, entered into a strategic partnership with Shanghai Junshi Biosciences Co., Ltd, which is a vital step in continuously enriching its portfolio of high-value pipelines in the immunology and inflammation fields.
Importance 80.0 Sentiment 65.0
per
Jianjun Zou
Jianjun Zou, General Manager and CEO of Shanghai Junshi Biosciences Co., Ltd, expressed optimism about the strategic collaboration with Fosun Pharmaceutical Group, highlighting its importance for expanding autoimmune disease treatments and accelerating roconkibart's advancement.
Importance 40.0 Sentiment 60.0
per
Li Jing
Li Jing, Co-President of Fosun Pharmaceutical Group and Chairman of Fosun International — Fosun Wanbang Pharma Group, emphasized the strategic partnership's role in addressing unmet clinical needs in autoimmune diseases and enriching Fosun Pharmaceutical Group's immunology and inflammation portfolio.
Importance 40.0 Sentiment 60.0
cnt
China
The licensing agreement covers the Greater China region, including the Chinese mainland, China — Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan, indicating the geographical scope of the drug's commercialization.
Importance 30.0 Sentiment 0.0
govactor
China — National Medical Products Administration
The China — National Medical Products Administration accepted the new drug application for roconkibart in December 2025, indicating progress in the regulatory approval process for the drug.
Importance 20.0 Sentiment 0.0
cnt
Taiwan
Taiwan is part of the Greater China region covered by the licensing agreement for roconkibart.
Importance 10.0 Sentiment 0.0
loc
China — Macau
Macao Special Administrative Region is part of the Greater China region covered by the licensing agreement for roconkibart.
Importance 10.0 Sentiment 0.0
loc
China — Hong Kong
China — Hong Kong Special Administrative Region is part of the Greater China region covered by the licensing agreement for roconkibart.
Importance 10.0 Sentiment 0.0
Relationships
China related ↔ China — National Medical Products Administration
China adversary ↔ Taiwan China claims Taiwan as its own territory and frequently conducts aggressive military blockade drills, refusing to rule o
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.